Correction to: CCAAT/enhancer binding protein α predicts poorer prognosis and prevents energy starvation–induced cell death in hepatocellular carcinoma (Hepatology, (2015), 61, 3, (965-978), 10.1002/hep.27593);CCAAT/enhancer binding protein α predicts poorer prognosis and prevents energy starvation-induced cell death in hepatocellular carcinoma

Hepatology

Volumn 61, Issue 3, 2015, Pages 965-978

  Lu, Guo Dong ^a,b   Ang, Yang Huey ^a   Zhou, Jing ^a,c   Tamilarasi, Jegadeesan ^a   Yan, Benedict ^a   Lim, Yaw Chyn ^a   Srivastava, Supriya ^d   Salto Tellez, Manuel ^e   Hui, Kam M ^f   Shen, Han Ming ^a   Nguyen, Long N ^g   Tan, Bryan C ^g   Silver, David L ^g   Hooi, Shing Chuan ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b GUANGXI MEDICAL UNIVERSITY   (China)

^c GUANGXI UNIVERSITY OF CHINESE MEDICINE   (China)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^f DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^g DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; CHLOROQUINE; FATTY ACID; GLUCOSE; GLUTAMINE; MEMBRANE PROTEIN; TMEM166 PROTEIN, HUMAN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOPHAGY; CALORIC INTAKE; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; CELL DEATH; CELL PROTECTION; CONTROLLED STUDY; FATTY ACID OXIDATION; FEMALE; GENE SILENCING; HUMAN; IN VITRO STUDY; LIPID METABOLISM; LIPOLYSIS; LIVER; LIVER CELL CARCINOMA; LIVER NECROSIS; LIVER NODULE; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STARVATION; SURVIVAL PREDICTION; TISSUE MICROARRAY; TUMOR NECROSIS; TUMOR XENOGRAFT; UPREGULATION; AGED; ANIMAL; BAGG ALBINO MOUSE; LIVER TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TUMOR CELL LINE;

ADULT; AGED; ANIMALS; AUTOPHAGY; CARCINOMA, HEPATOCELLULAR; CCAAT-ENHANCER-BINDING PROTEIN-ALPHA; CELL DEATH; CELL LINE, TUMOR; HUMANS; LIPID METABOLISM; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84923292207     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.30685     Document Type: Erratum

References (34)

1. Villanueva A, Hernandez-Gea V, Llovet JM. Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol 2013;10:34-42.
2. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
4. Schulze A, Harris AL. How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature 2012;491:364-373.
5. Huang Q, Tan Y, Yin P, Ye G, Gao P, Lu X, et al. Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics. Cancer Res 2013;73:4992-5002.
6. Beyoğlu D, Imbeaud S, Maurhofer O, Bioulac-Sage P, Zucman-Rossi J, Dufour JF, et al. Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification. Hepatology 2013;58:229-238.
7. Budhu A, Roessler S, Zhao X, Yu Z, Forgues M, Ji J, et al. Integrated metabolite and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes. Gastroenterology 2013;144:1066-1075, e1.
8. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429-442.
9. Koschmieder S, Halmos B, Levantini E, Tenen DG. Dysregulation of the C/EBPα differentiation pathway in human cancer. J Clin Oncol 2009;27:619-628.
10. Wang ND, Finegold MJ, Bradley A, Ou CN, Abdelsayed SV, Wilde MD, et al. Impaired energy homeostasis in C/EBP α knockout mice. Science 1995;269:1108-1112.
11. Matsusue K, Gavrilova O, Lambert G, Brewer HB Jr, Ward JM, Inoue Y, et al. Hepatic CCAAT/enhancer binding protein α mediates induction of lipogenesis and regulation of glucose homeostasis in leptin-deficient mice. Mol Endocrinol 2004;18:2751-2764.
12. Lu GD, Leung CH, Yan B, Tan CM, Low SY, Aung MO, et al. C/EBPα is up-regulated in a subset of hepatocellular carcinomas and plays a role in cell growth and proliferation. Gastroenterology 2010;139:632-643, 643.e1-4.
13. Paz-Priel I, Ghosal AK, Kowalski J, Friedman AD. C/EBPα or C/EBPα oncoproteins regulate the intrinsic and extrinsic apoptotic pathways by direct interaction with NF-kappaB p50 bound to the bcl-2 and FLIP gene promoters. Leukemia 2009;23:365-374.
14. Wang L, Yu C, Lu Y, He P, Guo J, Zhang C, et al. TMEM166, a novel transmembrane protein, regulates cell autophagy and apoptosis. Apoptosis 2007;12:1489-1502.
15. Miranda DA, Koves TR, Gross DA, Chadt A, Al-Hasani H, Cline GW, et al. Re-patterning of skeletal muscle energy metabolism by fat-storage-inducing transmembreane protein 2. J Biol Chem 2011:286:42188-42199.
16. + T cell memory development. Immunity 2012;36:68-78.
17. Singh R, Kaushik S, Wang Y, Xiang Y, Novak I, Komatsu M, et al. Autophagy regulates lipid metabolism. Nature 2009;458:1131-1135.
18. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012;8:445-544.
19. Dufour A, Schneider F, Metzeler KH, Hoster E, Schneider S, Zellmeier E, et al. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol 2010;28:570-577.
20. Marcucci G, Maharry K, Radmacher MD, Mrózek K, Vukosavljevic T, Paschka P, et al. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol 2008;26:5078-5087.
21. Hackanson B, Bennett KL, Brena RM, Jiang J, Claus R, Chen SS, et al. Epigenetic modification of CCAAT/enhancer binding protein α expression in acute myeloid leukemia. Cancer Res 2008;68:3142-3151.
22. Jost E, do ON, Wilop S, Herman JG, Osieka R, Galm O. Aberrant DNA methylation of the transcription factor C/EBPα in acute myelogenous leukemia. Leuk Res 2009;33:443-449.
23. Pabst T, Eyholzer M, Haefliger S, Schardt J, Mueller BU. Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia. J Clin Oncol 2008;26:5088-5093.
24. Kirstetter P, Schuster MB, Bereshchenko O, Moore S, Dvinge H, Kurz E, et al. Modeling of C/EBPα mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells. Cancer Cell 2008;13:299-310.
25. Wang GL, Iakova P, Wilde M, Awad S, Timchenko NA. Liver tumors escape negative control of proliferation via PI3K/Akt-mediated block of C/EBP α growth inhibitory activity. Genes Dev 2004;18:912-925.
26. Wang GL, Timchenko NA. Dephosphorylated C/EBPα accelerates cell proliferation through sequestering retinoblastoma protein. Mol Cell Biol 2005;25:1325-1338.
27. Yin H, Lowery M, Glass J. In prostate cancer C/EBPα promotes cell growth by the loss of interactions with CDK2, CDK4, and E2F and by activation of AKT. Prostate 2009;69:1001-1016.
28. Paz-Priel I, Houng S, Dooher J, Friedman AD. C/EBPα and C/EBPα oncoproteins regulate nfkb1 and displace histone deacetylases from NF-kappaB p50 homodimers to induce NF-kappaB target genes. Blood 2011;117:4085-4094.
29. Bu SY, Mashek MT, Mashek DG. Suppression of long chain acyl-CoA synthetase 3 decreases hepatic de novo fatty acid synthesis through decreased transcriptional activity. J Biol Chem 2009;284:30474-30483.
30. Li LO, Ellis JM, Paich HA, Wang S, Gong N, Altshuller G, et al. Liver-specific loss of long chain acyl-CoA synthetase-1 decreases triacylglycerol synthesis and beta-oxidation and alters phospholipid fatty acid composition. J Biol Chem 2009;284:27816-27826.
31. Ha J, Daniel S, Broyles SS, Kim KH. Critical phosphorylation sites for acetyl-CoA carboxylase activity. J Biol Chem 1994;269:22162-22168.
32. Park JW, Finn RS, Kim JS, Karwal M, Li RK, Ismail F, et al. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2011;17:1973-1983.
33. Toh HC, Chen PJ, Carr BI, Knox JJ, Gill S, Ansell P, et al. Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma. Cancer 2013;119:380-387.
34. Soulen MC. Chemoembolization of hepatic malignancies. Oncology (Williston Park) 1994;8:77-84; discussion 84, 89-90.